NHS Patients Can't Opt Out of Palantir's Data Platform – but Their Hospital Can

Why It Matters

The ruling shapes patient privacy expectations and determines whether the NHS will continue relying on a controversial US‑based vendor for critical health data integration.

Key Takeaways

• Patients cannot opt out of Palantir's NHS data platform.
• 168 of 214 NHS trusts have adopted the Federated Data Platform.
• Trusts may opt out, but data use for direct care remains mandatory.
• Parliament urges ending Palantir involvement amid privacy concerns.
• Contract runs until Feb 2027; renewal decision due this year.

Pulse Analysis

The NHS Federated Data Platform, built by Palantir, consolidates patient information across hospitals, mental‑health services and integrated care boards. While the system promises faster analytics for care coordination, the National Data Opt‑Out—designed to protect secondary uses such as research—does not apply to the FDP because the data is classified as essential for direct patient care. This regulatory nuance has sparked a debate over whether patients truly retain control over their health records, especially as Palantir staff have recently gained an "admin" role that permits access to identifiable data.

Adoption has been rapid: 168 of the 214 NHS trusts have signed up, with 123 already operating the platform and 80 reporting measurable benefits, ranging from reduced duplication of tests to improved population‑health insights. Yet the rollout is not uniform; trusts retain the right to procure alternative solutions if they meet national standards. Parliamentary scrutiny has intensified, with the Science, Innovation and Technology Committee urging an end to Palantir’s involvement and MPs submitting 40 written questions about the vendor’s ties to U.S. intelligence agencies. The controversy underscores a broader tension between leveraging advanced data tools and maintaining public confidence in the NHS’s stewardship of sensitive health information.

Looking ahead, the contract is set to expire in February 2027, and a decision on renewal is due this year. While the FDP earned a green rating from the National Infrastructure and Service Transformation Authority—signalling it is on track—any continuation will require a robust exit and transition framework to safeguard data continuity. Should the government opt for a new supplier, it will face a complex procurement process and the logistical challenge of migrating vast datasets without disrupting patient services. The outcome will shape the NHS’s digital future, influencing how health data is shared, protected, and ultimately used to improve care outcomes across England.